185312-82-7

Basic information

• Product Name: 4-BROMO-2-CHLOROBENZOIC ACID METHYL ESTER
• Synonyms: 4-BROMO-2-CHLOROBENZOIC ACID METHYL ESTER;Methyl 4-bromo-2-chlorobenzoate;BENZOIC ACID,4-BROMO-2-CHLORO-,METHYL ESTER
• CAS NO: 185312-82-7
• Molecular Formula: C₈H₆BrClO₂
• Molecular Weight: 249.5
• Product Categories: Aromatic Esters
• Mol File: 185312-82-7.mol
• Article Data: 29

Chemical Properties

• Boiling Point: 295.117°C at 760 mmHg
• Flash Point: 132.282°C
• Appearance: /
• Density: 1.605g/cm³
• Vapor Pressure: 0.002mmHg at 25°C
• Refractive Index: 1.5770 to 1.5810
• Storage Temp.: Room temperature.
• CAS DataBase Reference: 4-BROMO-2-CHLOROBENZOIC ACID METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BROMO-2-CHLOROBENZOIC ACID METHYL ESTER(185312-82-7)
• EPA Substance Registry System: 4-BROMO-2-CHLOROBENZOIC ACID METHYL ESTER(185312-82-7)

Safety Data

• Hazardous Substances Data: 185312-82-7(Hazardous Substances Data)

Usage

General Description

4-Bromo-2-chlorobenzoic acid methyl ester is a chemical compound with the molecular formula C8H6BrClO2. It is a methyl ester derivative of 4-bromo-2-chlorobenzoic acid. 4-BROMO-2-CHLOROBENZOIC ACID METHYL ESTER is mainly used in research and industrial applications such as pharmaceuticals, dyes, and agrochemicals. It is also utilized in the synthesis of various organic compounds and can be used as a building block for more complex chemical structures. The compound may have potential uses in medicinal chemistry due to its structural properties, and its synthesis and properties are the subject of ongoing scientific research.

InChI:InChI=1/C8H6BrClO2/c1-12-8(11)6-3-2-5(9)4-7(6)10/h2-4H,1H3

Upstream product

• 59748-90-2 4-Bromo-2-chloro-benzoic Acid 
• 89794-02-5 4-bromo-2-chlorotoluene 
• 75-36-5 acetyl chloride 
• 67-56-1 methanol 
• 936-08-3 2-bromo-4-chlorobenzoic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 74-88-4 methyl iodide 

Downstream Products

• 98592-34-8 2-chloro-4-cyano benzoic acid methyl ester 
• 111986-07-3 methyl 2-chloro-4-(ethylsulfanyl)benzoate 
• 219767-64-3 methyl 4-benzylthio-2-chlorobenzoate 
• 219767-63-2 methyl 2-chloro-4-(n-pentanethio)benzoate 
• 908248-02-2 methyl 2-chloro-4-formylbenzoate 
• 908248-00-0 methyl 2-chloro-4-(2-cyclopropylethynyl)benzoate 
• 908247-98-3 methyl 2-chloro-4-(3,3-dimethylbut-1-ynyl)benzoate 
• 1059705-62-2 2-chloro-4-(4-methylpiperazin-1-yl)benzoic acid methyl ester 
• 185315-48-4 (4-bromo-2-chlorophenyl)methanol 
• 158435-41-7 4-bromo-2-chlorobenzaldehyde 

Relevant articles and documents

Compound serving as protein kinase inhibitor and application of compound

The invention discloses a compound used as a protein kinase inhibitor and application of the compound, the compound has an obvious inhibition effect on protein kinase activity, can be used as a BTK inhibitor for preparing medicines for treating BTK-mediated diseases such as malignant tumors, autoimmune diseases and the like, and has wide application prospect.

5-Aryl-1,3,4-oxadiazol-2-ylthioalkanoic Acids: A Highly Potent New Class of Inhibitors of Rho/Myocardin-Related Transcription Factor (MRTF)/Serum Response Factor (SRF)-Mediated Gene Transcription as Potential Antifibrotic Agents for Scleroderma

Through a phenotypic high-throughput screen using a serum response element luciferase promoter, we identified a novel 5-aryl-1,3,4-oxadiazol-2-ylthiopropionic acid lead inhibitor of Rho/myocardin-related transcription factor (MRTF)/serum response factor (SRF)-mediated gene transcription with good potency (IC50 = 180 nM). We were able to rapidly improve the cellular potency by 5 orders of magnitude guided by sharply defined and synergistic SAR. The remarkable potency and depth of the SAR, as well as the relatively low molecular weight of the series, suggests, but does not prove, that binding to the unknown molecular target may be occurring through a covalent mechanism. The series nevertheless has no observable cytotoxicity up to 100 μM. Ensuing pharmacokinetic optimization resulted in the development of two potent and orally bioavailable anti-fibrotic agents that were capable of dose-dependently reducing connective tissue growth factor gene expression in vitro as well as significantly reducing the development of bleomycin-induced dermal fibrosis in mice in vivo.

Stilbene Boronic Acids Form a Covalent Bond with Human Transthyretin and Inhibit Its Aggregation

Transthyretin (TTR) is a homotetrameric protein. Its dissociation into monomers leads to the formation of fibrils that underlie human amyloidogenic diseases. The binding of small molecules to the thyroxin-binding sites in TTR stabilizes the homotetramer and attenuates TTR amyloidosis. Herein, we report on boronic acid-substituted stilbenes that limit TTR amyloidosis in vitro. Assays of affinity for TTR and inhibition of its tendency to form fibrils were coupled with X-ray crystallographic analysis of nine TTR·ligand complexes. The ensuing structure-function data led to a symmetrical diboronic acid that forms a boronic ester reversibly with serine 117. This diboronic acid inhibits fibril formation by both wild-type TTR and a common disease-related variant, V30M TTR, as effectively as does tafamidis, a small-molecule drug used to treat TTR-related amyloidosis in the clinic. These findings establish a new modality for covalent inhibition of fibril formation and illuminate a path for future optimization.